Gilead Sciences, Inc. (GILD) Tops Q3 EPS by 1c, Sales Fall Inline
Tweet
Share
E-mailGet Alerts GILD Hot Sheet
Price: $150.89 +2.17%
Revenue Growth %: -0.3%
Financial Fact:
Cost of goods sold: 1.13B
Today's EPS Names:
ALZN, ASPU, USAU, More
Revenue Growth %: -0.3%
Financial Fact:
Cost of goods sold: 1.13B
Today's EPS Names:
ALZN, ASPU, USAU, More
Join SI Premium – FREE
Gilead Sciences, Inc. (NASDAQ: GILD) reported Q3 EPS of $1.02, $0.01 better than the analyst estimate of $1.01. Revenue for the quarter came in at $2.12 billion versus the consensus estimate of $2.11 billion.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gilead expands lenacapavir licensing to cover once-yearly HIV prevention
- LuxExperience B.V. (LUXE) Misses Q2 EPS by 11c
- Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
